Compared with traditional inactivated vaccines, mRNA vaccines have strong immunogenicity and can activate both humoral and cellular immunity. In addition, it has the advantages of a short development cycle, broad neutralization breadth, low cost, and a relatively simple manufacturing process that can be rapidly scaled to respond to sudden and rapidly mutating pandemic outbreaks. As a new vaccine technology, mRNA vaccines have many novel features and challenges. Taking the three coronavirus disease 2019(COVID-19) vaccines, BNT162b2 from Pfizer/BioNTech, mRNA-1273 from Moderna, and ARCoV developed by several Chinese institutions, as examples, this paper summarizes and analyzes the development and manufacturing strategy for mRNA vaccines in terms of antigen selection, nucleoside modification, and lipid nanoparticles(LNP) formulation preparation. The current challenges and future directions are discussed to contribute to a better understanding of mRNA vaccine technology.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |